Study of ALK drug resistance in lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study looks at why some lung cancers with an ALK gene change do not respond to ALK-targeted drugs. It may help find better treatments for patients whose cancer stops responding early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-small cell lung cancer (NSCLC) that was found to have an ALK gene fusion.
- Your cancer did not respond to an ALK-targeted drug or got worse within 3 to 6 months of starting treatment.
- You have not had any other cancer treatments besides the ALK drug.
- You are willing to have a tumor biopsy or blood draw for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
This trial looks at the genetic changes in non-small cell lung cancer (NSCLC) that has stopped responding to targeted therapy pills. It aims to understand why the cancer became resistant, which may help find better treatments.
This study looks at the genetic changes in ALK-positive lung cancer over time. It is for people who have already started one of three targeted treatments (alectinib, brigatinib, or lorlatinib) and are willing to provide extra tissue or blood samples for testing.
This study looks at biological changes in advanced lung cancer that has an ALK rearrangement, using regular blood samples (and sometimes tumor tissue if available). It may help researchers better understand how this cancer behaves and how it responds to first-line ALK-targeted treatment.
This trial looks at why ALK-positive lung cancer stops responding to the targeted drug lorlatinib, and what treatments might work next. It's for people whose cancer has progressed during first-line lorlatinib therapy.
This study looks at how people with advanced ALK-positive non-small cell lung cancer (NSCLC) respond to the targeted drug lorlatinib. It aims to understand whether local treatments (like radiation or surgery) are needed during therapy. If you have this type of lung cancer and haven't had treatment yet, this study might be an option.
Hear when a new NGS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.